Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TriSalus Life Sciences, Inc. - Common Stock (NQ:TLSI)

5.720 -0.010 (-0.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,747
Open 5.640
Bid (Size) 5.660 (3)
Ask (Size) 5.730 (2)
Prev. Close 5.730
Today's Range 5.370 - 5.770
52wk Range 3.500 - 10.24
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays Pessimistic
The company reaffirmed its previous guidance for 2025 and said it expects sales growth of over 50% and its gross margin to exceed 87%, higher than the 86% reported for 2024. 
Via Stocktwits
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
From TriSalus Life Sciences
Via Business Wire

Performance

YTD
+14.9%
+14.9%
1 Month
+3.6%
+3.6%
3 Month
+7.9%
+7.9%
6 Month
+43.4%
+43.4%
1 Year
-38.9%
-38.9%

More News

Read More
Examining the Future: TriSalus Life Sciences's Earnings Outlook
Via Benzinga
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping
From TriSalus Life Sciences
Via Business Wire
A Look Ahead: TriSalus Life Sciences's Earnings Forecast
Via Benzinga
Earnings Scheduled For March 27, 2025
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”
From TriSalus Life Sciences
Via Business Wire
3 Stocks With Robust Growth Outlooks Insiders Are Buying
Via MarketBeat
TriSalus Life Sciences Announces Key Appointments to Board of Directors
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
From TriSalus Life Sciences
Via Business Wire
TriSalus Announces Leadership Changes
From TriSalus Life Sciences
Via Business Wire
TriSalus Reports Q3 2024 Financial Results and Provides Business Update
From TriSalus Life Sciences
Via Business Wire
This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Monday
Via Benzinga
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer
From TriSalus Life Sciences
Via Business Wire
Earnings Scheduled For November 14, 2024
Via Benzinga
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
From TriSalus Life Sciences
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board
From TriSalus Life Sciences
Via Business Wire
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System
From TriSalus Life Sciences
Via Business Wire
TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace

Frequently Asked Questions

Is TriSalus Life Sciences, Inc. - Common Stock publicly traded?
Yes, TriSalus Life Sciences, Inc. - Common Stock is publicly traded.
What exchange does TriSalus Life Sciences, Inc. - Common Stock trade on?
TriSalus Life Sciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for TriSalus Life Sciences, Inc. - Common Stock?
The ticker symbol for TriSalus Life Sciences, Inc. - Common Stock is TLSI on the Nasdaq Stock Market
What is the current price of TriSalus Life Sciences, Inc. - Common Stock?
The current price of TriSalus Life Sciences, Inc. - Common Stock is 5.720
When was TriSalus Life Sciences, Inc. - Common Stock last traded?
The last trade of TriSalus Life Sciences, Inc. - Common Stock was at 04/28/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.